09.05.19
An update from Mallinckrodt Pharmaceuticals regarding their study VTS-270-303...
Read more07.05.19
We are happy to announce that the latest edition of NPUK News (Spring 2019) is here, full to the brim with everything our community needs - there's fundraising stories, events news, updates from staff and community members...and so much more!
Read more15.03.19
ALACHUA, FL – (Globe Newswire) – March 14, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical trial for treatment of Alzheimer’s Disease. The trial will use Trappsol® Cyclo™, the company’s proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously.
Read more11.03.19
IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC): OXFORD, UK, March 11, 2019-- IntraBio Inc., a late-stage biopharmaceutical company, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its Clinical Trial Authorisation (CTA) Application for Clinical Trial IB1001-201 with its lead compound (IB1001) for the treatment of Niemann-Pick disease Type C (NPC).
Read more01.03.19
Support is part of CTD’s efforts to recognize Rare Disease Day 2019...
Read more
